<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6515">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01867203</url>
  </required_header>
  <id_info>
    <org_study_id>CYPstatin001</org_study_id>
    <nct_id>NCT01867203</nct_id>
  </id_info>
  <brief_title>Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <authority>Belgium: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients needing lipid lowering therapy will be recruited before initiation of the
      treatment. For each patient, total and LDL cholesterol levels before start of therapy will
      be measured. One, three and six months after his/her first visit, when steady-state will be
      reached, for each included patient, the cholesterol levels will be re-assessed in order to
      evaluate the response to statin therapy calculated as the amplitude of cholesterol
      reduction. The aim is to assess the association between patient's genotype and the response
      to statin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Cholesterol levels-side effects</measure>
    <time_frame>1 to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy</condition>
  <arm_group>
    <arm_group_label>Statin users</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genotyping</intervention_name>
    <arm_group_label>Statin users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with statin drugs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient known to be compliant

          -  Age [25-80]

          -  treated with Atorvastatin, simvastatin, fluvastatin.

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laure Elens, PhD</last_name>
    <phone>+32 764 5351</phone>
    <email>laure.elens@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint-Luc Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haufroid Vincent, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laure Elens, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 29, 2013</lastchanged_date>
  <firstreceived_date>May 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Elens</investigator_full_name>
    <investigator_title>MSc, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
